Maybe Merck wanted the Phase II fully funded combination Keytruda & leronlimab trial shut down to give sufficient time to trial their own CCR5 blocker to see if they could get the same results as they saw in the murine study.

Now, that they proved their CCR5 blockade does not give similar results, Dr. Lalezari makes the switch to mCRC as #1 priority with hopes Merck requests that MD Anderson trial be reopened. Merck won't associate themselves with us any other way until that unassailable data is in our hands, but unfortunately, it is in the hands of MD Anderson.

Merck could buy that data and show it to their shareholders...